SETD2 mRNA Expression in Breast Cancer
Author Information
Author(s): W Al Sarakbi, W Sasi, WG Jiang, T Roberts, RF Newbold, K Mokbel
Primary Institution: St George's University of London
Hypothesis
Is the mRNA expression of SETD2 consistent with a tumor suppressive function in breast cancer?
Conclusion
SETD2 transcription levels are lower in cancerous tissues and in patients with progressive disease, suggesting a tumor suppressor role.
Supporting Evidence
- SETD2 mRNA levels were significantly lower in malignant samples compared to normal tissues.
- Lower SETD2 levels correlated with higher tumor stages.
- SETD2 expression was lower in patients who developed metastasis or died of breast cancer.
Takeaway
This study found that a gene called SETD2 is less active in breast cancer, which might mean it helps stop cancer from growing.
Methodology
Quantitative PCR was used to analyze mRNA expression levels of SETD2 in breast cancer and normal tissues.
Limitations
The study had a relatively small sample size and lacked data on protein expression.
Participant Demographics
{"node_status":{"node_positive":65,"node_negative":55},"tumor_grade":{"grade_1":23,"grade_2":41,"grade_3":56},"tumor_type":{"ductal":94,"lobular":14,"medullary":2,"tubular":2,"mucinous":4,"others":4},"tnm_staging":{"stage_1":69,"stage_2":40,"stage_3":7,"stage_4":4},"clinical_outcome":{"disease_free":81,"alive_with_metastasis":7,"local_recurrence":5,"died_of_breast_cancer":20,"died_of_unrelated_disease":7},"er_receptor_status":{"er_alpha_negative":26,"er_alpha_positive":62,"er_beta_negative":17,"er_beta_positive":71}}
Statistical Information
P-Value
p = 0.0345
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website